Immune Checkpoint Inhibitor-related Pneumonitis: Research Advances in Prediction and Management

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Mar 1

PMID 38426102

Authors

Mei-Xi Lin

Dan Zang

Chen-Guang Liu

Xu Han

Jun Chen

Affiliations

Soon will be listed here.

Abstract

The advent of immune-checkpoint inhibitors (ICIs) has revolutionized the treatment of malignant solid tumors in the last decade, producing lasting benefits in a subset of patients. However, unattended excessive immune responses may lead to immune-related adverse events (irAEs). IrAEs can manifest in different organs within the body, with pulmonary toxicity commonly referred to as immune checkpoint inhibitor-related pneumonitis (CIP). The CIP incidence remains high and is anticipated to rise further as the therapeutic indications for ICIs expand to encompass a wider range of malignancies. The diagnosis and treatment of CIP is difficult due to the large individual differences in its pathogenesis and severity, and severe CIP often leads to a poor prognosis for patients. This review summarizes the current state of clinical research on the incidence, risk factors, predictive biomarkers, diagnosis, and treatment for CIP, and we address future directions for the prevention and accurate prediction of CIP.

Citing Articles

Acute respiratory distress syndrome (ARDS): from mechanistic insights to therapeutic strategies.

Xie R, Tan D, Liu B, Xiao G, Gong F, Zhang Q MedComm (2020). 2025; 6(2):e70074.

PMID: 39866839 PMC: 11769712. DOI: 10.1002/mco2.70074.

The role of tumor types in immune-related adverse events.

Xu Q, Hu J, Wang Y, Wang Z Clin Transl Oncol. 2024; .

PMID: 39738878 DOI: 10.1007/s12094-024-03798-6.

Immune checkpoint inhibitor-related pneumonitis following discontinuation of pembrolizumab in a patient with advanced lung adenocarcinoma: a case report and literature review.

Wang H, Jin Y, Liu P, Zhou J, Fan N, Li M BMC Pulm Med. 2024; 24(1):597.

PMID: 39623374 PMC: 11613465. DOI: 10.1186/s12890-024-03424-9.

Bronchoscopic Diagnosis of Severe Respiratory Infections.

Roder M, Ng A, Morris A J Clin Med. 2024; 13(19).

PMID: 39408080 PMC: 11477651. DOI: 10.3390/jcm13196020.

Immune checkpoint inhibitor therapy‑related pneumonitis: How, when and why to diagnose and manage (Review).

Lavalle S, Masiello E, Valerio M, Aliprandi A, Scandurra G, Gebbia V Exp Ther Med. 2024; 28(4):381.

PMID: 39113908 PMC: 11304171. DOI: 10.3892/etm.2024.12670.

References

Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D . Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.00050-2017. View

Ishikawa N, Hattori N, Yokoyama A, Kohno N . Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig. 2012; 50(1):3-13. DOI: 10.1016/j.resinv.2012.02.001. View

Diehl A, Yarchoan M, Hopkins A, Jaffee E, Grossman S . Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget. 2018; 8(69):114268-114280. PMC: 5768402. DOI: 10.18632/oncotarget.23217. View

Albandar H, Fuqua J, Albandar J, Safi S, Merrill S, Ma P . Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?. Cancers (Basel). 2021; 13(5). PMC: 7956829. DOI: 10.3390/cancers13050989. View

Ciaurriz M, Zabalza A, Beloki L, Mansilla C, Perez-Valderrama E, Lachen M . The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients. Cell Mol Life Sci. 2015; 72(21):4049-62. PMC: 11113937. DOI: 10.1007/s00018-015-1986-z. View

Yeung C, Kartolo A, Holstead R, Moffat G, Hanna L, Hopman W . Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Diseases. J Immunother. 2021; 44(9):362-370. DOI: 10.1097/CJI.0000000000000377. View

Zhou C, Yang Y, Lin X, Fang N, Chen L, Jiang J . Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis. Front Immunol. 2022; 13:935779. PMC: 9364904. DOI: 10.3389/fimmu.2022.935779. View

Okada N, Matsuoka R, Sakurada T, Goda M, Chuma M, Yagi K . Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. Sci Rep. 2020; 10(1):13773. PMC: 7426925. DOI: 10.1038/s41598-020-70743-2. View

Atchley W, Alvarez C, Saxena-Beem S, Schwartz T, Ishizawar R, Patel K . Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina. Chest. 2021; 160(2):731-742. PMC: 8411447. DOI: 10.1016/j.chest.2021.02.032. View

10.

Lin X, Lu T, Li S, Xie X, Chen X, Jiang J . Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study. Clin Transl Oncol. 2020; 23(2):389-396. DOI: 10.1007/s12094-020-02432-5. View

11.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

12.

Suresh K, Naidoo J, Lin C, Danoff S . Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. Chest. 2018; 154(6):1416-1423. PMC: 6335259. DOI: 10.1016/j.chest.2018.08.1048. View

13.

Chuzi S, Tavora F, Cruz M, Costa R, Chae Y, Carneiro B . Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res. 2017; 9:207-213. PMC: 5476791. DOI: 10.2147/CMAR.S136818. View

14.

Li X, Lv F, Wang Y, Du Z . Establishment and validation of nomogram for predicting immuno checkpoint inhibitor related pneumonia. BMC Pulm Med. 2022; 22(1):331. PMC: 9436165. DOI: 10.1186/s12890-022-02127-3. View

15.

Barratt S, Flower V, Pauling J, Millar A . VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease. Int J Mol Sci. 2018; 19(5). PMC: 5983653. DOI: 10.3390/ijms19051269. View

16.

Jia X, Geng L, Jiang P, Xu H, Nan K, Yao Y . The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. J Exp Clin Cancer Res. 2020; 39(1):284. PMC: 7734811. DOI: 10.1186/s13046-020-01749-x. View

17.

Stroud C, Hegde A, Cherry C, Naqash A, Sharma N, Addepalli S . Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2017; 25(3):551-557. DOI: 10.1177/1078155217745144. View

18.

Kowalski B, Valaperti A, Bezel P, Steiner U, Scholtze D, Wieser S . Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study. J Cancer Res Clin Oncol. 2021; 148(7):1711-1720. PMC: 9189083. DOI: 10.1007/s00432-021-03750-z. View

19.

Abdel-Rahman O, Fouad M . Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis. 2016; 10(3):183-93. PMC: 5933609. DOI: 10.1177/1753465816636557. View

20.

Tone M, Izumo T, Awano N, Kuse N, Inomata M, Jo T . High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer. Thorac Cancer. 2019; 10(10):2006-2012. PMC: 6775002. DOI: 10.1111/1759-7714.13187. View